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Multiplesclerosis(MS)isaninflammatory,autoimmunediseaseofthecentralnervoussystem.Thecauseof
MS is still unknown but epidemiological and immunological studies have implicated Epstein-Barr virus
(EBV), which infects B cells, as a possible etiological agent involved in disease. Of particular interest is EBV
latent membrane protein 2A (LMP2A) because previous studies have demonstrated that LMP2A enhances
the expansion and differentiation of B cells upon antigen stimulation, revealing a potential contribution of
thisproteininautoimmunity.SinceBcellsarethoughttocontributetoMS,weexaminedtheroleofLMP2A
in the animal model experimental autoimmune encephalomyelitis (EAE). In this model, transgenic mice in
which B cells express LMP2A show increased severity and incidence of disease. This difference was not due
to lymphocyte recruitment into the CNS or differences in T cell activation, rather, we show that LMP2A
enhances antigen presentation function.
M
S is a chronic inflammatory disease of the central nervous system (CNS) that begins in early adulthood.
More than 1 million people worldwide and at least 350,000 people in the United States are affected with
MS
1. This disease is characterized by focal lesions of demyelination, which leads to episodic or pro-
gressive neurological disability
1. The cause and mechanisms of MS have yet to be determined, but it is thought to
arise via a combination of a genetic susceptibility, tissue damage, and environmental factors, such as a viral
infection
2 that may lead to a break in tolerance.
Infection with EBV, a B-lymphotropic gamma-herpesvirus, is correlated with MS and as such is a leading
candidate etiological factor in MS
1,3,4. Although the exact relationship between EBV infection and MS is not
clearlyidentified,MShasbeenassociatedwithlatentEBVinfectionofBcells.AsBcellsplayafundamentalrolein
immunity andbecausestudieshavealready outlinedthepotentialroleofthehumoral armoftheimmune system
in both MS
5–8 and EAE
5,9–11, B cell dysregulation through latent persisting viral infection may contribute to
autoimmunity.
Latent membrane protein 2A (LMP2A) is an EBV protein expressed during primary and latent infection and
has been extensively studied in transgenic models. These data indicate that LMP2A promotes B cell survival,
development,proliferation,anddifferentiation
12–14.Thus,dysregulationofnormalBcellfunctionbyLMP2Amay
constitute a mechanism underlying the role of EBV in autoimmunity.
ToinvestigatethehypothesisthatLMP2Amaycontributetoautoimmunity,weutilizedourtransgenicLMP2A
mice (Tg6) that express LMP2A at levels that do not significantly alter B cell development
15. Similar to earlier
studies using an animal model of systemic lupus erythematosus that determined that LMP2A induces autoreac-
tive B cell activation
16, we demonstrate that by enhancing antigen presentation function, LMP2A enhances
disease severity in an animal model of MS.
Results
LMP2AincreasesclinicalsymptomsofEAE.TodeterminewhethertheexpressionofLMP2AinBcellsaltersthe
development of EAE, transgenic LMP2A mice and litter mate controls (WT) were immunized with human
recombinant myelin oligodendrocyte glycoprotein (rMOG) in CFA and monitored for clinical disease
development. Human rMOG was used instead of MOG35–55 peptide because B cells were revealed to be
important when immunizing with protein and not peptide
11, and with human rMOG and not rat rMOG
17.
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SCIENTIFIC REPORTS | 2 : 353 | DOI: 10.1038/srep00353 1LMP2A mice developed slightly worse disease than did litter mate
controls(Figure1).LMP2Amicehaveahigherdiseaseincidenceand
peak score and develop more severe disease, although the day of
onset of disease is similar compared to litter mate controls (Table 1).
CNS lymphocyte infiltrates do not differ between LMP2A
transgenic mice and litter mate controls. To test the hypothesis
that differing cell infiltrating profiles between LMP2A mice and
litter mate controls could explain the enhanced clinical symptoms
of EAE, mononuclear cells were isolated from the CNS and
quantified during the pre-clinical (days 7–9), peak (days 15–16),
and chronic (days 22–24) stages of EAE. Figure 2a demonstrates
the flow cytometric gating strategy used to quantify total cells and
lymphocyte subsets. We observed similar numbers of total
infiltrating cells in brains (data not shown) and spinal cords of
both LMP2A mice and litter mate controls (Figure 2b) as well as in
the populations of CD3
1CD4
1, CD3
1CD8
1, and CD19
1 cells
(Figure 2c–e) at all three disease stages.
T Cell Activation in LMP2A transgenic mice and litter mate
controls are similar. Due to the lack of differences found in
the infiltrating cell populations in the CNS of mice throughout
EAE, we next determined if the T cell activation state may explain
differences in disease between LMP2A mice and litter mate controls.
Initially, bulk cells from lymph nodes and spleens from mice at the
pre-clinical, peak, and chronic stages of EAE were restimulated with
rMOG and proliferation was measured using
3H-thymidine
incorporation. Both lymph node cells (data not shown) and
splenocytes (Figure 3a) from LMP2A and litter mate control mice
proliferated similarly.
To examine the cytokine profile of cells during EAE, splenocytes
were collected at peak disease and restimulated with MOG35–55,a n
immunodominantdeterminantofMOG.Thecytokineprofilesinthe
culture supernatants were measured, demonstrating no difference in
IL-2(Figure3b),IFN-c(Figure3c),IL-17(data notshown),orTNF-
a levels (data not shown) between LMP2A and litter mates control
groups. Additionally, no difference wasfoundinlymph node cells or
at other stages of EAE (data not shown).
TofurtherexaminetheactivationstatusofTcellsduringEAE,cells
were isolated from spleen and lymph nodes at the pre-clinical, peak,
and chronic stages ofEAE and wererestimulated with MOG35–55 and
assessed for the number of IL-2 and IFN-c secreting cells. The num-
ber of IL-2 secreting cells from spleens (data not shown) and lymph
nodes did not differ between LMP2A and litter mate controls groups
throughout disease (Figure 3d). However, the number of IFN-c
secreting cells was enhanced at the pre-clinical disease stage in
LMP2A mice compared to litter mate controls (Figure 3e).
IgG1 levels are increased in LMP2A transgenic mice when
compared to litter mate controls. To determine if increased
autoantibody levels could explain the increased disease scores in
LMP2A mice, immunoglobulin ELISAs were performed to examine
the levels of total rMOG-specific IgG in serum collected from LMP2A
mice and litter mate controls at the pre-clinical, peak, and chronic
stages of EAE. No differences in rMOG-specific IgG between LMP2A
mice and litter mate controls were detected at pre-clinical (Figure 4a),
peak (data not shown), or chronic (data not shown) EAE. To examine
if B cells from mice were secreting differential levels of IgG isotypes,
cells from lymph nodes (Figure 4c–e) and spleens (Figure 4f–h) were
collected at the pre-clinical, peak, and chronic stages of EAE and the
number of rMOG-specific IgG1, IgG2a, and IgG2b antibody secreting
cells (ASCs) were assessed using an ELISPOT assay. The numbers of
rMOG-specific IgG2a and IgG2b secreting cells were similar in
LMP2A mice and litter mate controls at all stages of EAE. However,
in both lymph nodes and spleens, LMP2A mice had increased
numbers of rMOG-specific IgG1 secreting cells at the pre-clinical
disease stage (Figure 4c, f). The number of ASCs between
splenocytes and lymph node cells were similar. As support to the
finding of increased numbers of IgG1-secreting cells at pre-clinical
EAE, levels of rMOG-specific IgG1 were increased in serum of mice
at this stage of disease (Figure 4b).
Antigen presentation function is enhanced in LMP2A transgenic
mice when compared to litter mate controls. Because LMP2A is
known to enhance B cell activation
13,16, we wanted to determine
whether expression of LMP2A increased expression of MHC class
IIandco-stimulatorymoleculesinBcells.LMP2Amicewerecrossed
with BCR
MOG transgenic mice
18. B cells from double transgenic
(LMP2A-BCR
MOG) and litter mate control mice (WT-BCR
MOG)
were isolated and cultured with T cells isolated from TCR
MOG
mice
19 and rMOG. Flow cytometric analysis revealed that culture
with increased rMOG resulted in increased expression of MHC
class II, CD80, and CD86; however, increased expression of these
proteins were similar on both LMP2A and litter mate control B cells
(Figure 5a). Similarly, T cell activation markers CD25, CD44,
CD62L, and CD69 were also analyzed on the co-cultured T cells
and found to be expressed at control levels. (Figure 5b).
Since B cells are important professional antigen presenting
cells (APCs), we next investigated whether the expression of
LMP2A affected the antigen presenting function of B cells. Culture
Figure 1 | LMP2A increases clinical symptoms of EAE. Clinical scores of
rMOG/CFA1PTX-inducedEAEinLMP2Aandlittermatecontrol(WT)
mice were collected. A representative of three independent experiments is
shown, in which each data point represents the mean and 6 SEM of 6 WT
and 7 LMP2A mice.
Table 1 | LMP2A increases clinical symptoms of EAE
Incidence
a EAE onset, day
b Peak clinical score
c Cumulative disease score
d
WT 79% 6 9.7% 13.17 6 1.48 2.30 6 0.38* 23.33
LMP2A 92% 6 4.9% 13.05 6 1.18 2.71 6 0.48* 31.43
EAE clinical parameters were observed in rMOG-induced EAE in LMP2A and litter mate control (WT) mice. a–c, Each number represents the mean 6 SEM of at least three independent experiments, each
experiment including 3–6 WT and 5–10 LMP2A mice. d, Number represents the mean cumulative disease score of the representative disease course in Figure 1. Statistical difference of p50.0412 (*)f o r
LMP2A mice versus litter mate controls is indicated.
www.nature.com/scientificreports
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in antigen processing between control and LMP2A B cells
(Figure 6a). However, the proliferation of MOG-specific T cells sti-
mulated with rMOG in co-cultures with irradiated B cells from
LMP2A-BCR
MOG, as compared to B cells from WT-BCR
MOG mice,
wassignificantlyenhanced(Figure6b).Thisresultwasobservedwith
two different concentrations of rMOG and at two timepoints, and
reproducible with two separate preparations of rMOG protein.
To bypass processing of antigen, B cells from LMP2A-BCR
MOG
andWT-BCR
MOGmicewereculturedwithMOG35–55-specificTcells
Figure 2 | CNS lymphocyte infiltrates do not differ between LMP2A transgenic mice and litter mate controls. Mononuclear cells were isolated from
spinal cords of LMP2A and litter mate control (WT) mice at pre-clinical, peak, and recovery stages of disease. a, Flow cytometric gating strategy used to
quantify total cells and lymphocyte subsets. b, Enumeration of infiltrating cells in LMP2A and WT littermates at all three stages of disease using trypan
blue exclusion. c-e, Infiltrating cells were stained to identify CD45
hiCD19
1, CD45
hiCD3
1CD4
1, and CD45
hiCD3
1CD8
1 cells by flow cytometry at pre-
clinical (c), peak (d), and chronic (e) stages of EAE. Each number represents a mouse and shown is a representative of 3 (pre-clinical), 4 (peak), and 2
(chronic) experiments. Lines represent the mean of each group.
Figure 3 | T cell activation in LMP2A transgenic mice and litter mate controls (WT) are similar. a, Splenocytes from primed (solid lines) and naive
(dotted lines) mice at peak disease were restimulated with the indicated concentrations of rMOG and proliferation was determined via
3H-thymidine
incorporation. b and c, Splenocytes were collected at peak disease and restimulated with the indicated amount of rMOG. Supernatants from 3 days of
culture were analyzed for cytokine levels using cytokine bead array (CBA). d and e, Cells from lymph nodes were collected at pre-clinical, peak, and
chronicEAEandrestimulatedwithMOG35–55peptideandassessedforthenumberofIL-2andIFN-csecretingcellusingELISPOTdetection.Thevertical
bars represent mean 6 SD between triplicate wells. Statistical difference of p50.0046 (**) is indicated.
www.nature.com/scientificreports
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increased T cell proliferation as compared to B cells of litter mate
controls (Figure 6c). To investigate the need for processing of the
MOG35–55 peptide, B cells were fixed with paraformaldehyde to pre-
vent antigen processing but allow peptide loading. Cultures with
fixed B cells from LMP2A-BCR
MOG and WT-BCR
MOG mice induced
similar levels of T cell proliferation at two timepoints and three
concentrations of antigen (Figure 6d). As expected, culture with
rMOG protein and PFA-fixed B cells resulted in nominal T cell
proliferation (data not shown). Collectively LMP2A B cells exhibit
enhanced capacity to drive activation of naı ¨ve T cells.
Discussion
Inthecurrentstudy,weinvestigatedifEBVLMP2Ainfluences auto-
immunity using EAE, an accepted murine model of MS. LMP2A is
expressedinEBVlatentinfectionandisknowntoalternormalBcell
function. We found that clinical EAE scores were increased in
LMP2A mice compared to litter mate controls. This enhancement
was not due to do enhanced cell infiltration into the CNS or
enhanced T cell activation despite the observation in in vitro models
thatLMP2Aenhancescellmigration
20–22.Interestingly,levelsofIFN-
c-producing T cells and rMOG-specific IgG1 secreting cells were
increased during the pre-clinical stage of disease. Most significantly,
we found that LMP2A enhanced the APC function of B cells ex vivo,
whichmayprovideamechanisticexplanationforthecontributionof
EBV in autoimmune diseases such as MS. We suggest that increased
autoreactiveTcellactivationasaresultofLMP2AenhancementofB
cellAPCfunctionpromotesaninflammatoryenvironmentandfacil-
itates disease progression during disease initiation. In addition, the
increase in IFN-c at pre-clinical EAE may also contribute to exacer-
bateddisease.Followinginitiationofdisease,theroleofEBVLMP2A
in altering other aspects of B cell function may be obscured by the
robust T cell response, explaining the small differences in the pre-
clinical stage of EAE and the modest difference in overall disease
course.
The mechanism of how LMP2A enhances the antigen presenting
function of B cells remains unknown, although many studies have
revealed a role of LMP2A in altering signaling pathways leading to
celldysregulation
14,23,24.OnepossibilityisthatLMP2Aenhancestoll-
like receptor (TLR) sensitivity of B cells, which could lead to
enhanced APC function. Jiang et al. determined that TLR9 stimu-
lation enhanced the APC function of B cells
25, and Wang et al.
observed that LMP2A B cells were hypersensitive to TLR9 activa-
tion
16.TLRs,andinparticularTLR9,havealreadybeenimplicatedin
EAE disease progression
26,27. Whether expression of LMP2A in B
cells causes heightened sensitivities to TLR ligands in our model of
EAE, and if those changes in sensitivity affect APC function remain
interesting questions to address and is the focus of ongoing studies.
Figure 4 | IgG1levelsareincreasedinLMP2Atransgenicmicewhencomparedtolittermatecontrols. rMOG-specificantibodyproductionbyBcellsof
LMP2A mice and litter mates (WT) after rMOG-induced EAE were measured. a-b, ELISA of rMOG-specific IgG (a) and IgG1 (b) in 5-fold dilutions
(160X–500,000X) of serum collected from naı ¨ve (dotted lines) and pre-clinical EAE (solid lines) mice. Individual mouse serum samples were tested in
duplicate and the data is represented as mean 6 SD of 2 experiments, each experiment consisting of 2–4 mice per genotype. Statistical differences of
p50.0156 (*)o rp 50.0051 (**) at the specific dilutions are indicated. c–h, ELISPOT detection of rMOG-specific IgG isotypes produced by lymph node
(c–e) and spleen cells (f–h) at pre-clinical, peak, and chronic EAE after restimulation with MOG35–55 peptide. Data is graphed as percent wildtype and
shown are the means 6 SD of3 (pre-clinical), 4 (peak), and 2 (chronic) experiments. The range of spots detected per 500,000 cells plated were 34–90, 8–
43, 15–68 (IgG1), 18–48, 14–23, 47–52 (IgG2a), and 18–46, 18–34, 42–85 (IgG2b) for pre-clinical, peak, and chronic stages of EAE, respectively.
www.nature.com/scientificreports
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class II, CD80, and CD86 on B cells of LMP2A and litter mate con-
trols, distribution and concentration of these molecules within lipid
rafts, which has been shown to be important in the formation of
immunological synapses
28, may be altered by LMP2A, resulting in
enhanced T cell proliferation. The lack of difference between B cells
ofLMP2AandlittermatecontrolswhenPFA-fixedmaybeduetothe
loss of membrane fluidity, thereby disallowing LMP2A to enhance
concentration or cross-linkage of BCR complexes.
Alternatively, LMP2A may be involved in the processing and pre-
sentation of antigen instead of the initial signaling of the BCR com-
plexandsynapseformation.Inthiscase,LMP2Awouldplayarolein
the latter steps of antigen processing and presentation, as the endo-
cytic pathway and initial cleavage of antigen is intact in LMP2A B
Figure 5 | Levels of activation markers are similar between LMP2A transgenic mice and litter mate controls. T cells purified from TCR
MOG mice and B
cells purified from LMP2A-BCR
MOG (LMP2A) and WT-BCR
MOG control (WT) mice were co-cultured with the indicated concentrations of rMOG.
ExpressionofMHCII,CD80,andCD86onB220
1cells(a)andCD25,CD44,CD62L,andCD69onCD3
1cells(b)wereevaluatedafter24 hourofculture
using flow cytometry.
Figure 6 | Antigen presentation function is enhanced in LMP2A transgenic mice when compared to litter mate controls. a, Splenocytes from LMP2A
and litter mate control mice (WT) were cultured with different concentrations of self-quenching DQ-OVA, and FITC signal was measured from CD19
1
cells cultured at 37uC (solid lines) and 4uC (dotted lines). b-d,
3H-thymidine uptake by T cells purified from TCR
MOG mice and B cells purified from
LMP2A-BCR
MOG (LMP2A) and WT-BCR
MOG (WT) mice were measured after culturing with indicated concentrations of rMOG or MOG35–55 peptide.
Cellswereculturedforthree(b)orfour(candd)daysandpulsedwith
3H-thymidineforthefinal24 hours.Beforeculturing,Bcellswereirradiated(band
c)orfixedwithparaformaldehyde(d).Thedataarerepresentativeof2(a),5(b),3(c),and3(d)independentexperiments.Verticalbarsrepresentmean6
SD between triplicate wells. Statistical differences of p,0.05 (*)o rp ,0.01 (**) are indicated.
www.nature.com/scientificreports
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OVA. The effect of LMP2A on antigen presentation and processing
needstobefurtherexplored,suchasprocessingofprotein,trimming
of peptide, and transport through the Golgi apparatus.
Our initial observation of increased MOG-specific IgG1-secreting
cells in spleens and lymph nodes of mice at the pre-clinical stage of
disease was surprising due to the popular belief that EAE is consid-
ered a TH1 mediated disease and knowing that cytokines produced
by TH2 cells such as IL-4 promotes class switching to IgG1 isotypes.
However, the presence of IgG1 during or after an inflammatory
response has been reported: high titers of IgG1 autoantibodies are
detected in the double-transgenic BCR
MOG x TCR
MOG mice that
develop spontaneous opticospinal encephalomyelitis despite a lack
of increase in TH2 cytokines
29; the oligoclonal immunoglobulins
found in the cerebral spinal fluid of MS patients are predominantly
IgG1
30. In our model, LMP2A B cells may encounter increased levels
of TH2 cytokines pre-clinically, leading to IgG1 isotype switching.
During the remainder of the disease course and with TH1 cytokines,
however, B cells from LMP2A and litter mate controls could be
encountering the same cytokines, leading to the observed equivalent
levels of isotype switching to IgG1, IgG2a, and IgG2b.
PreviousstudiesofLMP2A-transgenicmicealsoindicatearolefor
this protein in the initial stages of autoimmunity. LMP2A has been
shown to bypass tolerance checkpoints
23 and enhance TLR sensitiv-
ity,aspreviouslymentioned
16.Thesecharacteristicsoranotherfactor
due to enhanced B cell signaling
13 could lead to enhanced antigen
processing and presentation. The contribution of latently infected B
cells as antigen presenting cells may be significant in the context of
MS, as myelin antigen would be limiting during the initiation
of disease and B cells have been shown to be important antigen
presenting cells when antigen is limiting
31,32.
The contribution of EBV in MS remains controversial, and
whether our results are reflective of the events in human disease
remains unknown. While EBV remains persistently infected in only
a small fraction of B cells in an individual
33, all B cells in our trans-
genic mice express LMP2A
34. Also, other viral proteins expressed
during latency may affect the role of LMP2A in EAE and MS.
These issues could begin to be addressed by adoptively transferring
known ratios of B cells from LMP2A and litter mate controls into B
cell deficient (mMT) mice, as well as using double transgenic mice
which B cells express both LMP2A and other latency proteins.
Our finding that LMP2A enhances antigen presentation of B cells
leadstoapuzzlingquestionofwhyEBVmightenhancehostcellAPC
function. Since mature, naı ¨ve B cells require encounter with antigen
to survive, infection of these cells leads to a perplexing situation in
whichabalancebetweenhostcellsurvivalandimmuneevasionmust
be maintained. While LMP2A enhances the survival of the host cell,
other viral factors may be involved in regulating this effect. For
example, gp42, a glycoprotein involved in EBV entry, binds MHC
class II and thus interferes with presentation of peptide to T cells
35.
Investigating other EBV proteins in addition to LMP2A will delin-
eate the individual and net effects of viral proteins on APC function.
Alternatively, the effects of LMP2A on B cell APC function may be
indirect. In response to LMP2A signaling, B cells may have evolved
ananti-viralstrategybyenhancingimmunesurveillance.AlthoughB
cells normally maintain a balance between immunodeficiency and
autoimmunity, infection with EBV may tip the balance of B cells
towards promoting autoimmunity.
In conclusion, we demonstrate that LMP2A enhances EAE sever-
ity and antibody production at the pre-clinical stage of disease. We
alsoobserved thatthis latencyproteinenhancesB cellAPCfunction.
Collectively, these findings provide a novel potential mechanism to
explain how latent EBV infection may contribute to autoimmune
diseases, including MS. Further studies are required to definitively
delineate the mechanism(s) by which LMP2A enhances antigen pre-
sentation and how this results in exacerbated disease.
Methods
Mice. LMP2A transgenic mice were created in a C57BL/6 background as previously
described. MOG
TCR (2D2) mice were purchased from The Jackson Laboratory (Bar
Harbor,ME)andhavebeenpreviouslydescribed.MOG
BCR(IgH)micewereobtained
from the Kuchroo laboratory (Harvard Medical School, Boston, MA). All mice were
bred and housed under specific pathogen-free (SPF) conditions in the Center for
ComparativeMedicine,NorthwesternUniversity.Allexperimentswereperformedin
accordance with institutional and NIH guidelines and approved by the Animal Care
and Use Committee at Northwestern University.
MOG peptide and protein. Synthetic peptide MOG35–55
(MEVGWYRSPFSRVVHLYRNGK) was purchased from Genemed Synthesis (San
Francisco, CA). Escherichia coli DH5a bacteria expressing the extracellular 125
amino acid domain of human MOG proteins were obtained from the Ruddle
laboratory(YaleUniversitySchoolofMedicine,NewHaven,CT)andtheproteinwas
purified as previously described. Briefly, the bacteria were grown in antibiotic-
supplemented Luria-Bertani broth and induced to overexpress hexahistidine-tagged
MOG. The protein was then denatured, purified via Ni-NTA Agarose (Qiagen), then
refolded.
Induction and Evaluation of EAE. Six- to eight-wk-old C57Bl/6 mice were
immunized subcutaneously with 100 ml of an emulsion containing 100 mg of rMOG
and 200 mgo fMycobacterium tuberculosis H37Ra (BD Biosciences, San Jose, CA)
distributed over three sites on the flank. Mice were injected intraperitoneally with
200 ngofpertussistoxin(PTX)(ListBiologicalLaboratories,Cambell,CA)ondays0
and 2 post-immunization. Clinical scores were given on a scale of 0 to 5 based on the
following symptoms: 0 5 healthy; 1 5 limp tail; 2 5 mild hind limb weakness; 3 5
severe hind limb weakness; 4 5 hind limb paralysis; 5 5 moribund. Immunologic
analyses were carried out at pre-clinical (days 7–9), peak (days 15–16), and chronic
(days 22–24) stages of EAE.
Cell Isolation. Isolation of CNS-infiltrating mononuclear cells from the CNS was
performed as similarly described
36, by isolating brains and spinal cords from PBS-
perfused mice and treated with a solution of 0.2 Wn/ml Liberase R1 (Roche Applied
Science), 50 mg/ml DNase I, and 25 mMHepes in balanced salt solution and mashed
through wire screens to obtain single cell suspensions. Cells were washed in 5 mM
EDTA-Hank’s balanced salt solution before a Percoll (Amersham, Piscataway, NY)
gradient was used to isolate mononuclear cells. For spleen and lymph node, tissues
were dissociated through wire screens to obtain single cell suspensions. Red blood
cells were lysed in 155 mM ammonium chloride. Cells were then filtered through
40 mmnylonmesh.ForAPCexperiments,CD19
1Bcells(fromLMP2A-BCR
MOGand
WT-BCR
MOG mice) and T cells (from TCR
MOG mice) were purified to approximately
90 to 95% purity via magnetic cell sorting (MACS) columns utilizing magnetic beads
coated with antibodies specific for CD19 or CD4 (Miltenyi Biotec, Auburn, CA,
USA). CD19
1 B cells were irradiated or fixed in 1% paraformaldehyde for 8 minutes
at room temperature before 100,000 each of CD19
1 B cells and T cells were cultured.
PeripheralInVitroAntigen-SpecificProliferationAssay.Spleensandlymphnodes
(cervical, axillary, brachial, and inguinal) were harvested and mashed through wire
screens. 5 3 10
5 erythrocyte-free cells per well were incubated in complete RPMI
(consisting of RPMI 1640 [cellgro], 10% fetal bovine serum, 50 uM b-
mercaptoethanol, 50 U/mlpenicillin,and 50 mg/mlstreptomycin)withMOG35–55at
37uCi n5 %C O 2 for 72 hours in 96-well round-bottom microtiter plates, then pulsed
with 1 mCi/well
3H-thymidine for the final 24 hours of culture. Uptake of
3H-
thymidine was detected using a Topcount Microplate Scintillation Counter. For
antigen presentation experiments, cells were also cultured with indicated amounts of
rMOG protein and B cells were irradiated with 818 rad or fixed with 1%
paraformaldehyde.
Flow cytometric analysis. Single cell suspensions of spleen, lymph node, brain, and
spinal cord tissue were stained with the following monoclonal rat anti-mouse
antibodies:CD3e(PE-Cy7),CD45(APC),MHCIII-A/I-E(PE),CD80(FITC),CD86
(APC),CD25(APC-Cy7),CD62L(APC),CD69(FITC)fromeBioscience(SanDiego,
CA), or CD4 (FITC), CD8a (APC-Cy7), CD19 (PE), B220 (PerCP), CD3 (PerCP),
CD44 (PE) from BD Biosciences (San Jose, CA). 0.5 ml antibody was added per
500,000 cells and incubated at 4uC for 30minutes in 2% FBS-PBS. For APC
experiments analyzing co-stimulatory molecules, cells were first incubated with
LIVE/DEAD Fixable Violet Dead Cell Stain from Invitrogen (Carlsbad, CA) to
exclude dead cells. Cells were analyzed using a FACSCanto II machine (BD
Biosciences) and FlowJo software (Treestar, Ashland, OR).
Enzyme-linkedimmunosorbentassay(ELISA).ForserumELISA,serialdilutionsof
serum were applied to flat-bottom 96-well plates (Thermo Scientific) coated with
0.25 mg/wellrMOGandincubatedfor1 hourat37uCafterblockingwithasolutionof
PhosphateBuffered Saline, 0.05%Tween-20,and 5%Bovine Serum Albumin (PBST-
BSA). 10 ng/well of polyclonal anti-mouse IgG antibody (eBiosciences) or
monoclonal anti-mouse IgG1 antibody (clone A85-1) (BD Biosciences) was
incubatedfor1 hourat37uC,1:10,000dilutionofhorseradishperoxidase-conjugated
streptavidin (Amersham Biosciences) for 30 min. at 37uC, and finally TMB One
Component HRP Microwell Substrate and 450 nM Liquid Stop Solution (BioFX)
were each applied to the wells. Plates were washed with PBST between steps except
before application of Stop Solution. A SpectraMax M2 Microplate Readers
www.nature.com/scientificreports
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wavelengthof450 nm.ForcytokineELISA,supernatantsfromculturewerecollected
and analyzed via standard protocols for Cytometric Bead Array (CBA) (BD
Biosciences).
Enzyme-linked immuno-spot assay (ELISPOT). 350 ml, 0.45 mm PVDF UniFilter
plates (Whatman, GE Healthcare) were coated with 0.4 mg/well purified antibody
against IL-2 (clone JES6-1A12, eBiosciences) or IFN-c (clone R4-6A2), or 0.25 mg/
well rMOG and incubated overnight at 4uC. 500,000 erythrocyte-free cells per well
wereincubatedincompleteRPMIfor24 hrs.at37uCwith5%CO2.ForIL-2andIFN-
cplates,100 uMMOG35-55werealsoaddedwiththecells.Afterwashing,biotinylated
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eBiosciences), IFN-c (clone XMG1.2, eBiosciences), IgG1 (clone A85-1), IgG2a[b]
(clone 5.7), IgG2b (clone R12-3), and IgM (R6-60.2). The plates were then incubated
with an alkaline phosphatase-conjugated anti-biotin antibody (Vector Labs,
Burlingame, CA) for 1 hr. at 37uC and developed using AP Conjugate Substrate Kit
(Bio-Rad Laboratories, Hercules, CA). Spots were counted on an ELISPOT plate
reader (Cellular Technologies Ltd., Shaker Heights, OH). All antibodies are from BD
Biosciences unless indicated.
Statistical Analysis. Graphs are presented as mean 6 standard error of the mean
(SEM) or standard deviation (SD). Statistical analysis was performed with the
GraphPad Prism 5.0. Differences between multiple independent experiments were
determined with paired, 2-tailed Student’s t-test. Unpaired, 2-tailed Student’s t-test
was used in Figure 3e and 4b. Two-way Anova was used in Figure 6b and 6c. P values
less than 0.05 were considered significant (*); p values less than 0.01 were considered
very significant (**).
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